Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Jan 1;21(1):211-20.
doi: 10.1158/1078-0432.CCR-14-1816. Epub 2014 Oct 27.

Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis

Qian Zhong  1 , Hong-Ling Peng  1 , Xia Zhao  1 , Lin Zhang  2 , Wei-Ting Hwang  3
Affiliations
Meta-Analysis

Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis

Qian Zhong et al. Clin Cancer Res. .

Abstract

Purpose: To estimate the effects of BRCA1 and BRCA2 mutations on ovarian cancer and breast cancer survival.

Experimental design: We searched PubMed and EMBASE for studies that evaluated the associations between BRCA mutations and ovarian or breast cancer survival. Meta-analysis was conducted to generate combined HRs with 95% confidence intervals (CI) for overall survival (OS) and progression-free survival (PFS).

Results: From 1,201 unique citations, we identified 27 articles that compared prognosis between BRCA mutation carriers and noncarriers in patients with ovarian or breast cancer. Fourteen studies examined ovarian cancer survival and 13 studies examined breast cancer survival. For ovarian cancer, meta-analysis demonstrated that both BRCA1 and BRCA2 mutation carriers had better OS (HR, 0.76; 95% CI, 0.70-0.83 for BRCA1 mutation carriers; HR, 0.58; 95% CI, 0.50-0.66 for BRCA2 mutation carriers) and PFS (HR, 0.65; 95% CI, 0.52-0.81 for BRCA1 mutation carriers; HR, 0.61; 95% CI, 0.47-0.80 for BRCA2 mutation carriers) than noncarriers, regardless of tumor stage, grade, or histologic subtype. Among patients with breast cancer, BRCA1 mutation carriers had worse OS (HR, 1.50; 95% CI, 1.11-2.04) than noncarriers but were not significantly different from noncarriers in PFS. BRCA2 mutation was not associated with breast cancer prognosis.

Conclusions: Our analyses suggest that BRCA mutations are robust predictors of outcomes in both ovarian and breast cancers and these mutations should be taken into account when devising appropriate therapeutic strategies.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Flow diagram for selection of studies
Fig.2
Fig.2
Forest plots of associations between BRCA mutations and ovarian cancer survival.(A) Effect of BRCA1 mutation on OS,(B) Effect of BRCA1 mutation on PFS,(C) Effect of BRCA2 mutation on OS,(D) Effect of BRCA2 mutation on PFS.
Fig.3
Fig.3
Forest plots of associations between BRCA mutations and breast cancer survival. (A) Effect of BRCA1 mutation on OS, (B) Effect of BRCA1 mutation on PFS, (C) Effect of BRCA2 mutation on OS, (D) Effect of BRCA2 mutation on PFS.
See this image and copyright information in PMC

Comment in

References

    1. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4:511–8. - PubMed
    1. Orban TI, Olah E. Emerging roles of BRCA1 alternative splicing. Molecular pathology : MP. 2003;56:191–7. - PMC - PubMed
    1. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307:382–90. - PMC - PubMed
    1. Safra T, Lai WC, Borgato L, Nicoletto MO, Berman T, Reich E, et al. BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(Suppl 8):viii63–viii8. - PubMed
    1. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 2012;30:2654–63. - PMC - PubMed

Publication types